Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (October 2024)
36 slides from Volitionrx's investor presentation, October 2024
Slide 1: Corporate Deck
Corporate Deck October 2024 Property Propertyof Volition©©2024 ofVolition 2024 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Our mission is to save lives and improve outcomes
Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Property Propertyof Volition©©2024 ofVolition 2024 Slide 3
Slide 4: Summary
Summary • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of or in addition to the genome • Disease areas – global killers: Cancer, Sepsis; significant market opportunities • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatm
Slide 5: What sets us apart?
What sets us apart? • Our tests are simple, low-cost accessible routine blood tests • Platform agnostic, can be adapted to any diagnostic workflow • Manual, Reference Lab, Specialist Lab and Point of Care Six Hours <10 minutes 45 minutes 20 minutes <15 minutes • Our expanding Intellectual Property p
Slide 6: Commercial Strategy: Licensing
Commercial Strategy: Licensing Overall approach • R&D conducted by Volition and its research partners • Monetize our IP through commercial contracts with upfront payments, milestone payments, royalties and sales of key components • Appointed PharmaVentures July ’24 to lead transactions for oncology
Slide 7: The Science Behind Our Technologies
The Science Behind Our Technologies Chromatin Chromosome Nucleosome Cancer and cell death cause chromatin CTCF fragmentation Sequence only present on CTCF in cancer Property of Volition© 2024 Slide 7
Slide 8: Nu.Q Vet Cancer Test
Nu.Q® Vet Cancer Test Property of Volition Veterinary Diagnostics Development© 2024 Slide 8
Slide 9: Licensing & Supply Agreements to-date
Licensing & Supply Agreements to-date • Launched with IDEXX in the U.S Jan ‘23 • Launched in U.S. / Aus • Launched in UK & Ireland Nov ‘23 /HK/Singapore/ some EU countries April ‘24 • Launched July ‘24 • Launched in Portugal • Launched in Nov ‘22 Singapore Nov ‘23 • Launched in Taiwan Nov ‘23 • Laun
Slide 10: Now available in 16 countries and growing
Now available in 16 countries and growing! Property of Volition Veterinary Diagnostics Development© 2024 Slide 10
Slide 11: Launched April 2024 (Heska agreement)
Launched April 2024 Exclusive agreement with Heska providing in- hospital access to Nu.Q® $10M upfront and $13M milestone payments received to-date. $5M milestone payment linked to use in felines remaining Launched APRIL 2024 Ongoing revenue from the purchase of kits and key components Property of V
Slide 12: Launched April 2024
Launched April 2024 Rapid (<10 mins) Accurate (detects 76% of systemic cancers at 97% specificity) Cost effective ($35 to the vet) Allowing veterinarian to make informed clinical decisions quickly – whilst the patient is still in clinic Property of Volition Veterinary Diagnostics Development© 2024 S
Slide 13: Development Pipeline
Development Pipeline Screening & Platform Monitoring development Cancer in : automated Cats Treatment & Disease NETosis in Monitoring animals Application Property of Volition Veterinary Diagnostics Development© 2024 Slide 13
Slide 14: Commercial Performance
Commercial Performance • Received $23 million in upfront and milestone payments to-date • >60,000 tests sold in H1 2024 (including components for the Point-of-Care test) compared to 58,000 sold in 2023 • Test is now available in 16 countries and growing • Target for 2024 is to triple the # of tests
Slide 15: Sepsis & Thrombosis
Sepsis & Thrombosis Property of Volition© 2023 2024 Slide 15
Slide 16: Neutrophil Extracellular Traps (NETs)
Neutrophil Extracellular Traps (NETs) NETs: • are produced by ejecting chromosomal material out of the cell • catch and kill bacteria and viruses • can sterilize blood in minutes • first reported in 20041 • now the subject of > 5000 publications 1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhle
Slide 17: 1 in 5 deaths worldwide are associated with sepsis
1 in 5 deaths worldwide are associated with sepsis It’s the number 1... Almost 50 million cases resulting in Cause of death in Over 40% of 11 million deaths hospitals survivors suffer from long-term physical Over 40% of cases Cause for hospital or psychological are children under readmissions effec
Slide 18: Unmet Needs
Unmet Needs • Current diagnosis is empirical, multi-factorial and subjective. • CURRENT methods of assessment (SOFA and APACHE II) are both complex & slow. • Accepted need for improved diagnostics1. 1. Rudd et al. 2020 The Lancet doi: 10.1016/S0140-6736(19)32989-7. Property of Volition© 2024 Slide 1
Slide 19: Studies at Centers of Excellence: >3000 patients
Studies at Centers of Excellence: >3000 patients Study Country Description Cohort Size SISPCT Germany Retrospective analysis of 971 intensive care patients prospectively collected cohort Multiple timepoints Amsterdam Netherlands Retrospective analysis of 1,713 intensive care patients UMC prospective
Slide 20: Executive Summary: consolidated conclusions
Executive Summary: consolidated conclusions Results from three independent studies totalling over 3,000 patients These findings are consistent across cohorts1-3 An elevated H3.1 level reflects a dysregulated immune response and is associated with: • a risk of increased mortality • an increased risk
Slide 21: NETs: Casting a new light on sepsis management
NETs: Casting a new light on sepsis management Satellite Symposium at ESICM LIVES 2024 Prof. Djillali Annane Professor of Medicine, University Paris Saclay-UVSQ, France “As a Critical Care Consultant, I see the devastating effects of this disease each day. I believe Nu.Q® NETs, as a diagnostic tool,
Slide 22: Our focus…
Our focus… To develop a low-cost, routine test to stratify risk of sepsis particularly those at risk of progressing to multiple organ failure; in addition to monitoring the disease progression and response to treatment. • Data from several large-scale studies presented at ESICM LIVES 20241 • Manuscr
Slide 23: Property of Volition © 2024 Slide 23
Property of Volition© 2024 Slide 23
Slide 24: Low-cost, routine and accessible tests
• Low-cost, routine and accessible tests to help detect and monitor disease progression and aid treatment selection Property of Volition© 2024 Slide 24
Slide 25: Study Overviews & Upcoming Milestones
Study Overviews & Upcoming Milestones • Range of studies from prospective and retrospective, blinded, longitudinal studies of lung cancer. • Cohort sizes – ranging from 70 to 800 patients. • Covering detection of lung cancer at diagnosis and during treatment • KEY Outcome measures to demonstrate CLI
Slide 26: Potential applications of a blood test in cancer
Potential applications of a blood test in cancer Nu.Q® addresses all five Property of Volition© 2024 Slide 26
Slide 27: Our Focus
Our Focus To develop low-cost, routine tests to help: • detect disease early • provide tailored treatment • assess response to treatment • identify MRD • support continued treatment decisions Many data in the Confidential Data Room and submission for peer review in H2 2024 and publication thereafter
Slide 28: Proof of Concept
Proof of Concept: Potential Breakthrough Cancer Detection Method1. • Novel wet chemistry pathway for ctDNA analysis • Discovered a completely new class of biomarkers that are invisible to current methods and demonstrated that they can be isolated as pure ctDNA • Identified hundreds of potential shor
Slide 29: Summary & Financial Update
Summary & Financial Update Property Propertyof Volition©©2024 ofVolition 2024 Slide 29
Slide 30: Commercial Strategy: Licensing
Commercial Strategy: Licensing Overall approach • R&D conducted by Volition and its research partners • Monetize our IP through commercial contracts with upfront payments, milestone payments, royalties and sales of key components • Appointed PharmaVentures July ’24 to lead transactions for oncology
Slide 31: Summary
Summary • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of or in addition to the genome • Disease areas – global killers: Cancer, Sepsis; significant market opportunities • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatm
Slide 32: Key Financials Second Quarter 2024
Key Financials Second Quarter 2024 NYSE American Market: VNRX Market Cap: $67.2m* 52-week range: $0.43-$1.23* Net cash used in operating activities:12-month average ~$1.4m/mth** Cash-on-hand: ~$6m** * As of Subsequent to quarter end completed a registered direct offering of Oct 16, 2024 common stock
Slide 33: Questions?
Questions? Thank you for your interest in Volition. For more details, please visit www.volition.com Property Propertyof Volition©©2024 ofVolition 2024 Slide 33
Slide 34: The Team
The Team Property Propertyof Volition©©2024 ofVolition 2024 Slide 34
Slide 35: Executive Team
Executive Team Cameron Reynolds MBA, President & Group Chief Executive Officer - Cameron has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director
Slide 36: Executive Team (continued)
Jake Micallef PhD MBA, Chief Scientific Officer - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from King’s College